Hosted by Dr Andree Bates · 🇺🇸 US · EN · 216 episodes
Established thought leaders with verified media credentials.
AI For Pharma Growth is the podcast from pioneering Artificial Intelligence entrepreneur Dr. Andree Bates created to help Pharma, Biotech and other Healthcare companies understand how the use of AI-based technologies can easily save them time and grow their brands and company results.This show blends deep experience in the sector with demystifying AI for biopharma execs from biotech start-ups right through to big pharma. In this podcast, Dr Andree will teach you the tried and true secrets to building results in a pharma company using AI and alert you to some fascinating new tools and applications to benefit you and your company.As the author of many peer-reviewed journals in pharma AI, and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI, futuretech, healthcare and pharma to help you to navigate through the, sometimes confusing, but magical world of AI powered tools to achieve real-world results. This podcast feat
Dr Andree Bates hosts AI For Pharma Growth, a technology show with 216 episodes published.
For most of modern medicine, biological data has been built around population averages: what people like you might experience, rather than what you personally will. In this episode, Dr Andree Bates speaks with Ken Clark,
Most pharma companies are racing to apply AI across drug discovery, development and commercialisation, but many of those efforts will fail for one simple reason: the data underneath is not good enough. In this episode, D
On 7 May 2026, the EU reached a provisional agreement to push back the hardest deadlines in the EU AI Act. Many leadership teams heard one message: “we’ve got more time”. In this solo episode, Dr Andree Bates explains wh
In pharma, the biggest deals are increasingly won or lost before a formal process even begins. In this episode, Dr Andree Bates interviews Andrey Doronichev, co-founder and CEO of Bioptic, about the “intelligence gap” in
Real world evidence (RWE) could transform drug development and clinical care, but most organisations still struggle to turn messy clinical data into decisions they can trust. In this episode, Dr Andree Bates speaks with
Some of the most powerful breakthroughs happen when methods built for one discipline get turned on another. In this episode, Dr Andree Bates interviews Dr Irina Babina, CEO of Concr, on how computational techniques origi
Pharma doesn’t have an AI experimentation problem. It has an AI execution, scaling, and ROI justification problem. In this solo episode, Dr Andree Bates names one of the most expensive failure patterns in the industry: p
Cell therapies have huge potential, but cost, complexity, and centralised manufacturing have kept many of them confined to last-line use. In this episode, Dr Andree Bates speaks with Armon Sharei , Founder and CEO of Por
Clinical trial site selection is one of the biggest hidden bottlenecks in drug development, and it’s still often driven by legacy relationships, spreadsheets, and habit. In this episode, Dr Andree Bates interviews Simon
For many life sciences teams, the first wave of AI has looked like copilots: smart search, quick answers, and help on demand. Useful, but passive. In this episode, Dr Andree Bates is joined by Parth Khanna, CEO and co-fo
Many pharma and life science organisations have been investing in AI for years: pilots across commercial, medical, regulatory, and R&D, innovation labs, steering committees, vendor spend, and genuine effort from smart te
AI ethics has moved from theory to urgent necessity, especially as AI systems become embedded in healthcare, business decisions, and society at large. In this episode, Dr Andree Bates is joined by Dr Nadia Morozova, foun
Digital biomarkers are turning everyday movement into clinically useful data, giving doctors a clearer picture of what’s happening between appointments, and giving pharma new ways to measure drug impact earlier and more
Digital twins have become one of the most promising tools in Alzheimer’s research, but the bigger story is what happens when they scale across disease areas. In this episode, Dr Andree Bates interviews Aaron Smith, Found
AI in drug development is moving beyond “failure prevention” into something much bigger: redesigning how we discover, develop, and deliver medicines. In this episode, Dr Andree Bates speaks with Vitalay Fomin of Numenos
Enterprise AI is shifting from experiments to infrastructure, and that changes everything. In this episode, Dr Andree Bates interviews Jocelyn Houle, Senior Director of Product Management at Securiti.ai, to explore the f
Clinical trials are a massive industry with brutal economics, long timelines, and failure rates that would be unacceptable in almost any other sector. In this episode, Dr Andree Bates is joined by Dr Joseph Geraci of Net
AI capability has never been higher, yet most pharma AI programmes are still failing to create measurable business impact. In this solo episode, Dr Andree Bates breaks down why many pharma and biotech AI strategies are “
Healthcare accessibility is still being held hostage by phone queues, missed calls, and clunky portals. In this episode, Dr Andree Bates sits down with Josh Taylor of TxtSquad to explore why simple, secure texting can re
As artificial intelligence becomes increasingly woven into everyday life, the real question isn’t just what AI can do — it’s what it should do for humans. In this episode, Dr Andree Bates interviews Dr Morteza Zihayat of
Aaron Smith
Provincial Medical Executive Director for Northern Zone and Operational Co-Lead, Primary Care Clinics and Health Homes · Washington State Army National Guard
1 appearance on this show
Josh Taylor
former executive pastor turned chief marketing officer · Old Thunder Brewing
1 appearance on this show
Anthony Franco
founder of the world's first UX agency · First Strategy
1 appearance on this show
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
AI For Pharma Growth has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their technology audience.
AI For Pharma Growth is hosted by Dr Andree Bates. The show is categorised under technology and has published 216 episodes.
AI For Pharma Growth has published 216 episodes.
AI For Pharma Growth regularly covers technology. It sits in the technology category.
AI For Pharma Growth is accessible for guests with genuine technology expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
AI For Pharma Growth hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of AI For Pharma Growth average 33 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates AI For Pharma Growth's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 8 days ago.
